WHEAT RIDGE, Colo.–(BUSINESS WIRE)–Mar 28, 2013–Positive clinical outcomes continue to be reported by researchers worldwide with transcatheter aortic valve implantation (TAVI). Moreover, new technologies are in development and will, in the future, offer additional minimally invasive treatment options for diseased aortic and mitral valves in patients ineligible for surgery. To assist with the research and development of these new technologies, BDC Laboratories provides innovative and advanced product offerings to support medical device companies in evaluating their next-generation implants.
Accelerated wear testing (AWT) of heart valves offers the ability to evaluate and characterize the chronic wear of valve leaflets in a predictable, controlled, and reproducible manner, and demonstrates how a device may perform throughout its chronic use in-vivo. Cardiac valve accelerated wear testing guidelines are outlined in greater detail in the ISO 5840 guidance document.
Craig Weinberg, Ph.D., one of the principals of BDC Laboratories said, “Our new VDT-3600i AWT system is based on our proven, patent-pending technology and is designed to meet the needs of TAVI implants as well as novel, minimally invasive mitral valve technologies still in the development phase. Our VDT-3600i test system, coupled with our pulsatile hydrodynamic test system will continue to provide companies with a proven platform to aid in the development and evaluation of heart valve substitutes.” ABOUT BDC LABORATORIES: Biomedical Device Consultants and Laboratories (BDC Laboratories) offers test systems and testing services to the medical device industry that provide functional mechanical evaluation of medical device technologies as they relate to clinical outcomes. For over 35 years, BDC has been offering testing services and equipment to support research and development, and functional product evaluation, for regulatory submission of vascular grafts, endovascular stents, catheters, and heart valve technologies.
